CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Prostate Cryoablation (Whole-Gland) — Coverage Criteria

This policy governs coverage of whole-gland cryoablation (cryoablation/cryotherapy/cryosurgery) of the prostate for commercially insured members of Blue Cross Blue Shield - Rhode Island; Medicare Advantage plans are handled separately.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyProstate Cryoablation (Whole-Gland) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 17, 2021

Next Review DateN/A

Key ActionVerify member-specific benefits and eligibility with the provider call center prior to services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

55873CPT code listed as medically necessary

C61, D07.5…ICD-10 covered

Commercial onlyPlan applicability

Initial or salvageTreatment intent

Coverage Criteria for Prostate Cryoablation

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial or salvage whole-gland cryoablation: Whole gland cryoablation of the prostate may be considered medically necessary as treatment of clinically localized (organ-confined) prostate cancer when performed as initial treatment or as salvage treatment of disease that recurs following radiotherapy.

Applies to Commercial Products only; Medicare Advantage handled separately.

Provider Actions and Billing Notes

Prior Authorization

Prior authorization is not applicable for this policy.

Note

Verify Member Benefits

Benefits and coverage may vary between groups and contracts. Coverage is subject to the member's Evidence of Coverage and Subscriber Agreement; providers should verify member-specific benefits, eligibility, and prior authorization requirements by calling the provider call center.

Refer to the member's Evidence of Coverage and Subscriber Agreement for applicable covered and Not Medically Necessary benefits.
Verify eligibility and benefits with the provider call center before rendering services.

Denial Risk

Benefit Variability and Denial Risk

Coverage decisions may be denied or adjusted based on the member's contract and benefit limitations. Providers should confirm that services meet medical necessity and contract terms to avoid denials or member liability.

Coverage is determined by the member's Evidence of Coverage, Subscriber Agreement, and employer agreement.
If services are determined not medically necessary or are non-covered, the provider must obtain the member's written agreement before billing the member directly.

Background

Cryoablation (also called cryotherapy or cryosurgery) for prostate cancer is a percutaneous procedure in which cryoprobes are inserted into the prostate to rapidly freeze and thaw tissue, causing necrosis. This policy focuses on whole-gland (total) cryoablation when used as initial definitive therapy or as salvage treatment following radiotherapy; subtotal (focal) cryoablation is an emerging technique discussed in evidence reviews but is not the primary focus of this coverage policy.

Definitions

Cryoablation (cryoablation/cryotherapy/cryosurgery)

ProcedurePercutaneous insertion of cryoprobes into the prostate to rapidly freeze and thaw tissue, causing necrosis.

Also known asCryotherapy or cryosurgery.

MechanismExtremely cold gas is delivered down thin, needle-like cryoprobes to freeze and thaw targeted tissue.

Primary purposeDestruction of prostate cancer cells via freeze–thaw injury.

Whole-gland cryoablation

DefinitionCryoablation applied to the entire (whole) prostate gland as a definitive therapy.

Use casesCan be used as initial treatment for clinically localized (organ‑confined) prostate cancer or as salvage therapy after radiotherapy.

Evidence focusThis policy’s evidence review emphasizes total (whole‑gland) cryoablation rather than focal approaches.

Subtotal (focal) cryoablation

DefinitionSubtotal (focal) cryoablation targets part of the prostate rather than the entire gland.

StatusDescribed as an emerging technique and considered separately in evidence reviews.

Relation to policyNot the primary focus of this policy, which centers on whole‑gland (total) cryoablation.